Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statistical requirements of phase I studies.

L Edler1

  • 1Abteilung Biostatistik, Deutsches Krebsforschungszentrum, Heidelberg, FRG.

Onkologie
|April 1, 1990
PubMed
Summary

This study reviews phase I oncology trial design, focusing on dose selection and escalation. It highlights statistical needs and contrasts traditional methods with newer, pharmacokinetically guided approaches for better drug development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Not Available].

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2016
Same author

A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

European journal of cancer (Oxford, England : 1990)·2014
Same author

Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Investigational new drugs·2010
Same author

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome.

British journal of cancer·2010
Same author

10 Years CESAR Anticancer Drug Research - The 7th CESAR Annual Meeting 2009. Preface.

International journal of clinical pharmacology and therapeutics·2010
Same author

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

International journal of clinical pharmacology and therapeutics·2010

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Biostatistics

Background:

  • Phase I studies are critical for linking preclinical findings to clinical efficacy in oncology drug development.
  • Accurate determination of human starting dose, maximum tolerable dose (MTD), and dose escalation schemes are key methodological aspects.
  • Current practices require statistical rigor for effective planning and evaluation of early-phase oncology trials.

Purpose of the Study:

  • To outline the methodological and statistical requirements for planning and evaluating phase I oncology studies.
  • To differentiate between individual- and population-based approaches for defining the maximum tolerable dose (MTD).
  • To evaluate existing dose escalation schemes and introduce pharmacokinetically guided alternatives.

Main Methods:

  • Review of methodological aspects including human starting dose, MTD definition, and dose escalation strategies.
  • Statistical analysis of requirements for phase I study design.
  • Comparative analysis of the modified Fibonacci dose escalation scheme versus pharmacokinetically guided dose escalation.

Main Results:

  • The distinction between individual- and population-based MTD approaches is crucial for accurate definition and statistical parameter estimation.
  • The modified Fibonacci dose escalation scheme exhibits weaknesses compared to pharmacokinetically guided methods.
  • There is an urgent need for applying robust statistical methodologies in current phase I oncology trial practice.

Conclusions:

  • Phase I study design requires careful consideration of dose-finding methodologies and statistical principles.
  • Pharmacokinetically guided dose escalation offers potential advantages over traditional schemes.
  • Comprehensive phase I/II information processing is recommended to validate and improve current practices in oncology drug development.

Related Experiment Videos